Li Jiang

Li Jiang

Auto-generated profile, based on publicly available information

Li Jiang

31Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SVSriram Venneti
Sriram Venneti
AKAbed Rahman Kawakibi
Abed Rahman Kawakibi
SJSunjong Ji
Sunjong Ji
SWSebastian M. Waszak
Sebastian M. Waszak
SSStefan R. Sweha
Stefan R. Sweha
CKCarl Koschmann
Carl Koschmann
Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this finding remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/cerebrospinal fluid (CSF) correlate samples from patients treated in two completed multisite clinical studies. Patients treated with ONC201 following initial radiation but prior to recurrence demonstrated a median overall survival of 21.7 months, whereas those treated after recurrence had a median overall survival of 9.3 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle–related genes in baseline tumor sequencing. ONC201 treatment increased 2-hydroxyglutarate levels in cultured H3K27M-DMG cells and patient CSF samples. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuroglial differentiation genes. Overall, ONC201 demonstrates efficacy in H3K27M-DMG by disrupting integrated metabolic and epigenetic pathways and reversing pathognomonic H3K27me3 reduction. Significance: The clinical, radiographic, and molecular analyses included in this study demonstrate the efficacy of ONC201 in H3K27M-mutant DMG and support ONC201 as the first monotherapy to improve outcomes in H3K27M-mutant DMG beyond radiation. Mechanistically, ONC201 disrupts integrated metabolic and epigenetic pathways and reverses pathognomonic H3K27me3 reduction. This article is featured in Selected Articles from This Issue, p. 2293

27 June 2013 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
LJLi Jiang
Li Jiang
PMParul Mishra
Parul Mishra
RHRyan T. Hietpas
Ryan T. Hietpas
KZKonstantin B. Zeldovich
Konstantin B. Zeldovich
DBDaniel N. A. Bolon
Daniel N. A. Bolon
In natural systems, selection acts on both protein sequence and expression level, but it is unclear how selection integrates over these two dimensions. We recently developed the EMPIRIC approach to systematically determine the fitness effects of all possible point mutants for important regions of essential genes in yeast. Here, we systematically investigated the fitness effects of point mutations in a putative substrate binding loop of yeast Hsp90 (Hsp82) over a broad range of expression strengths. Negative epistasis between reduced expression strength and amino acid substitutions was common, and the endogenous expression strength frequently obscured mutant defects. By analyzing fitness effects at varied expression strengths, we were able to uncover all mutant effects on function. The majority of mutants caused partial functional defects, consistent with this region of Hsp90 contributing to a mutation sensitive and critical process. These results demonstrate that important functional regions of proteins can tolerate mutational defects without experimentally observable impacts on fitness. Changes in protein sequence or expression strength can both lead to adaptation in natural systems. While many studies have focused individually on either expression strength or protein sequence, in principle the fitness effects of these two protein properties are interdependent. We systematically investigated the fitness effects of both expression strength and protein sequence for the yeast Hsp90 gene (Hsp82). We analyzed the fitness effects of all possible point mutations in a putative substrate binding loop under seven different expression strengths. The fitness effects of amino acid substitutions were strongly dependent on expression strength. Many point mutations exhibited fitness defects at reduced expression strength that were hidden at the natural expression strength. Revealing these hidden mutant defects suggested that this region of Hsp90 contributes to a rate-limiting step in function, consistent with its putative role in substrate binding. This study is important because it indicates that critical regions in proteins are more prevalent than would be estimated based on experimental fitness analyses performed at natural expression strengths. As hidden fitness effects are likely to occur in other systems, these findings have broad implications for the field of experimental evolution.

28 October 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
EPEshini Panditharatna
Eshini Panditharatna
JMJoana G. Marques
Joana G. Marques
TWTingjian Wang
Tingjian Wang
MTMaria C. Trissal
Maria C. Trissal
ILIlon Liu
Ilon Liu
MFMariella G. Filbin
Mariella G. Filbin
Diffuse midline gliomas are uniformly fatal pediatric central nervous system cancers that are refractory to standard-of-care therapeutic modalities. The primary genetic drivers are a set of recurrent amino acid substitutions in genes encoding histone H3 (H3K27M), which are currently undruggable. These H3K27M oncohistones perturb normal chromatin architecture, resulting in an aberrant epigenetic landscape. To interrogate for epigenetic dependencies, we performed a CRISPR screen and show that patient-derived H3K27M-glioma neurospheres are dependent on core components of the mammalian BAF (SWI/SNF) chromatin remodeling complex. The BAF complex maintains glioma stem cells in a cycling, oligodendrocyte precursor cell–like state, in which genetic perturbation of the BAF catalytic subunit SMARCA4 (BRG1), as well as pharmacologic suppression, opposes proliferation, promotes progression of differentiation along the astrocytic lineage, and improves overall survival of patient-derived xenograft models. In summary, we demonstrate that therapeutic inhibition of the BAF complex has translational potential for children with H3K27M gliomas. Significance: Epigenetic dysregulation is at the core of H3K27M-glioma tumorigenesis. Here, we identify the BRG1–BAF complex as a critical regulator of enhancer and transcription factor landscapes, which maintain H3K27M glioma in their progenitor state, precluding glial differentiation, and establish pharmacologic targeting of the BAF complex as a novel treatment strategy for pediatric H3K27M glioma. See related commentary by Beytagh and Weiss, p. 2730. See related article by Mo et al., p. 2906. This article is highlighted in the In This Issue feature, p. 2711

1 February 2016 in Journal of Molecular Biology
Verified
Journal Article
Closed access
LJLi Jiang
Li Jiang
PLPing Liu
Ping Liu
CBClaudia Bank
Claudia Bank
NRNicholas Renzette
Nicholas Renzette
KPKristina Prachanronarong
Kristina Prachanronarong
DBDaniel N.A. Bolon
Daniel N.A. Bolon

7 November 2016 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
MDMaria Duenas-Decamp
Maria Duenas-Decamp
LJLi Jiang
Li Jiang
DBDaniel Bolon
Daniel Bolon
PCPaul R. Clapham
Paul R. Clapham
The conformation of HIV-1 envelope (Env) glycoprotein trimers is key in ensuring protection against waves of neutralizing antibodies generated during infection, while maintaining sufficient exposure of the CD4 binding site (CD4bs) for viral entry. The CD4 binding loop on Env is an early contact site for CD4 while penetration of a proximal cavity by CD4 triggers Env conformational changes for entry. The role of residues in the CD4 binding loop in regulating the conformation of the trimer and trimer association domain (TAD) was investigated using a novel saturation mutagenesis approach. Single mutations identified, resulted in distinct trimer conformations affecting CD4bs exposure, the glycan shield and the TAD across diverse HIV-1 clades. Importantly, mutations that improve access to the CD4bs without exposing the immunodominant V3 loop were identified. The different trimer conformations identified will affect the specificity and breadth of nabs elicited in vivo and are important to consider in design of Env immunogens for vaccines. Spike proteins on the surface of HIV virus particles bind to CD4 receptors on the surface of immune cells and trigger infection. The immune system in an infected person attacks the virus spikes by producing antibodies that bind and neutralize them. To combat this immune attack, HIV continually alters the structure of the spike and thus escapes host antibodies. However, this process must still preserve sites on the spike that bind CD4 receptors for infection. Here, we investigated how the spike regulates its structure. We used a systematic approach to investigate every possible mutation covering a region of the spike critical for binding the CD4 receptor and controlling overall structure. We identified different sites and mechanisms that control the spike structure for diverse HIV-1 strains and impact the exposure of the binding site for CD4 along with targets for neutralizing antibodies. Our observations will help guide the design of spike structures for vaccines that induce neutralizing antibodies effective against different HIV-1 strains across the globe.

27 May 2021 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
DLDaniela Lötsch
Daniela Lötsch
DKDominik Kirchhofer
Dominik Kirchhofer
BEBernhard Englinger
Bernhard Englinger
LJLi Jiang
Li Jiang
KOKonstantin Okonechnikov
Konstantin Okonechnikov
JGJohannes Gojo
Johannes Gojo
Ependymomas (EPN) are central nervous system tumors comprising both aggressive and more benign molecular subtypes. However, therapy of the high-risk subtypes posterior fossa group A (PF-A) and supratentorial RELA-fusion positive (ST-RELA) is limited to gross total resection and radiotherapy, as effective systemic treatment concepts are still lacking. We have recently described fibroblast growth factor receptors 1 and 3 (FGFR1/FGFR3) as oncogenic drivers of EPN. However, the underlying molecular mechanisms and their potential as therapeutic targets have not yet been investigated in detail. Making use of transcriptomic data across 467 EPN tissues, we found that FGFR1 and FGFR3 were both widely expressed across all molecular groups. FGFR3 mRNA levels were enriched in ST-RELA showing the highest expression among EPN as well as other brain tumors. We further identified high expression levels of fibroblast growth factor 1 and 2 (FGF1, FGF2) across all EPN subtypes while FGF9 was elevated in ST-EPN. Interrogation of our EPN single-cell RNA-sequencing data revealed that FGFR3 was further enriched in cycling and progenitor-like cell populations. Corroboratively, we found FGFR3 to be predominantly expressed in radial glia cells in both mouse embryonal and human brain datasets. Moreover, we detected alternative splicing of the FGFR1/3-IIIc variant, which is known to enhance ligand affinity and FGFR signaling. Dominant-negative interruption of FGFR1/3 activation in PF-A and ST-RELA cell models demonstrated inhibition of key oncogenic pathways leading to reduced cell growth and stem cell characteristics. To explore the feasibility of therapeutically targeting FGFR, we tested a panel of FGFR inhibitors in 12 patient-derived EPN cell models revealing sensitivity in the low-micromolar to nano-molar range. Finally, we gain the first clinical evidence for the activity of the FGFR inhibitor nintedanib in the treatment of a patient with recurrent ST-RELA. Together, these preclinical and clinical data suggest FGFR inhibition as a novel and feasible approach to combat aggressive EPN.